Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13390239 | 0.93 | ADORA1 (0.74) | ADORA1SLC6A3 | |
| SCHEMBL12536059 | 0.92 | ADORA1 (0.75) | ADORA1SLC6A3 | |
| SCHEMBL12536113 | 0.91 | ADORA1 (0.74) | ADORA1SLC6A3 | |
| SCHEMBL7602034 | 0.91 | ADORA1 (0.69) | ADORA1SLC6A3 | |
| Capadenoson SCHEMBL174016 | 0.91 | ADORA1 (1.00) | ADORA1SLC6A3 | |
| SCHEMBL7602658 | 0.91 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL12869980 | 0.91 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL13390321 | 0.90 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL7604784 | 0.90 | ADORA1 (0.67) | ADORA1SLC6A3 | |
| SCHEMBL7602046 | 0.89 | ADORA1 (0.67) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155336-A1 | PROCESS FOR THE PREPARATION OF 2-{4-[2-({[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]METHYL}SULFANYL)-3,5-DICYAN0-6-(PYRROLIDIN-1-YL)PYRIDIN-4-YL]PHENOXY}ETHYL-L-ALANYL-L-ALANINATE MONOHYDROCHLORIDE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-07 | — | — | US | disclosed |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9205077-B2 | 2-alkoxy-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20150306084-A1 | ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | BAYER IP GMBH (DE) | 2015-10-29 | — | — | US | disclosed |
| US-9040566-B2 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER IP GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-8957017-B2 | Dipeptoid prodrugs and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20140296515-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140296295-A1 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8791146-B2 | 2-alkoxy-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2012-05-17 | — | — | US | disclosed |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-12-01 | — | — | US | disclosed |
| US-20110136871-A1 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING AKTIENGESELLSCHAFT (DE) | 2011-06-09 | — | — | US | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20100197609-A1 | ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS | Bayer Schering Pharma (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7709504-B2 | Use of Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | BAYER HEALTHCARE AG LAW AND PATENTS,PATENTS AND LICENSING (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | BAYER HEALTHCARE AG | 2008-12-11 | — | — | US | disclosed |
| US-20080249133-A1 | Use of Substituted 2-Thio-3,5-Dicyano-4-Phenyl-6-Aminopyridines In the Treatment of Nausea and Vomiting | BAYER HEALTHCARE AG (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | ADORA1, ADORA2B, ADORA2A | ADORA1 1/4885SLC6A3 2970/4885 |
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | TPMT, DPP4, PYGL | ADORA1 1087/4885SLC6A3 825/4885 |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | TNNI3, QDPR, RYR2 | ADORA1 2751/4885SLC6A3 2984/4885 |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | PPIP5K2, TPMT, PNPO | ADORA1 2110/4885SLC6A3 3269/4885 |
| US-20110136871-A1 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, TNNT2 | ADORA1 2520/4885SLC6A3 2080/4885 |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | OTC, SDHA, SDHB | ADORA1 1133/4885SLC6A3 1807/4885 |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DPP7 | ADORA1 826/4885SLC6A3 594/4885 |
| US-20140296295-A1 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, TNNT2 | ADORA1 2520/4885SLC6A3 2080/4885 |
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | ADORA1 755/4885SLC6A3 612/4885 |
| US-20100197609-A1 | ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS | DNPEP, DDC, AADAC | ADORA1 755/4885SLC6A3 687/4885 |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885SLC6A3 1206/4885 |
| US-20180155336-A1 | PROCESS FOR THE PREPARATION OF 2-{4-[2-({[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]METHYL}SULFANYL)-3,5-DICYAN0-6-(PYRROLIDIN-1-YL)PYRIDIN-4-YL]PHENOXY}ETHYL-L-ALANYL-L-ALANINATE MONOHYDROCHLORIDE | PHYKPL, AASDHPPT, PAH | ADORA1 3585/4885SLC6A3 3031/4885 |
| US-20080249133-A1 | Use of Substituted 2-Thio-3,5-Dicyano-4-Phenyl-6-Aminopyridines In the Treatment of Nausea and Vomiting | TPMT, QDPR, KCNH1 | ADORA1 243/4885SLC6A3 57/4885 |
| US-20150306084-A1 | ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ADORA1, ADORA3, ADORA2A | ADORA1 1/4885SLC6A3 1547/4885 |
| US-20140296515-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | AADAT, DDC, DNPEP | ADORA1 402/4885SLC6A3 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.